Changes in brain amyloid-β accumulation after donepezil administration
Changes in brain amyloid-β accumulation after donepezil administration
复制标题
DOI：
10.1016/j.jocn.2017.08.025
复制
发表时间：
2017-11-01
影响因子：
2
通讯作者：
Ishii, Kenji
中科院分区：
文献类型：
--
作者：
Ishibashi, Kenji;Miura, Yoshiharu;Ishii, Kenji
最近使用阿尔茨海默病(AD)小鼠模型的研究表明，多奈哌齐给药减少了大脑淀粉样β蛋白(Aβ)的积累。这项研究调查了多奈哌齐是否可以减少AD患者脑内Aβ的蓄积。10名AD患者接受了大约一年间隔的两次C-11-匹兹堡化合物B正电子发射断层扫描，以测量多奈哌齐治疗前后脑内Aβ的蓄积。将感兴趣的体积放置在所有优先区域，并以小脑为参照区计算标准化摄取值比(SUVR)。3名和7名患者分别接受了10毫克和5毫克的多奈哌齐治疗。第二次治疗的UVR显著高于第一次治疗(P=0.026)。这项研究表明，服用多奈哌齐一年并不能减少人类阿尔茨海默病患者脑内Aβ的蓄积。(C)2017爱思唯尔有限公司。保留所有权利。
Recent studies using the mouse model of Alzheimer's disease (AD) have shown that donepezil administration reduces brain amyloid-beta (A beta) accumulation. This study investigated whether donepezil administration can reduce brain A beta accumulation in human patients with AD. Ten patients with AD underwent two C-11-Pittsburgh Compound B positron emission tomography sessions approximately one year apart to measure brain A beta accumulation before and after donepezil treatment. Volumes-of-interest were placed on All-preferred regions, and the standardized uptake value ratio (SUVR) was calculated considering the cerebellum as a reference region. Three and seven patients received 10 mg and 5 mg of donepezil, respectively. SUVR was significantly higher in the second than in the first session (P = 0.026). This study showed that one year of donepezil administration does not reduce brain A beta accumulation in human patients with AD. (C) 2017 Elsevier Ltd. All rights reserved.